SemSure - Accurate and reliable pregnancy detection for your next step

Clinical Certainty Before Unnecessary Hormones

Every year, millions of women consume high-dose emergency hormonal pills following intimate doubt or barrier slip, without knowing if semen was ever deposited. SemSure replaces guesswork with laboratory clarity.

SemSure Podium Background
SemSure Rapid Semen Detection Kit

SemSure Diagnostic Kit

Rapid lateral flow immuno-chromatographic assay

Results in 10–15 Minutes

Fast, equipment-free testing at home right when clarity matters most.

99% Sensitivity & 100% Specificity

Dual-biomarker multiplex detection targeting Semenogellin and PAP.

Zero Hormonal Interference

Eliminates anxiety-driven overuse of emergency hormonal contraceptive pills.

Backed by IIT Guwahati BioNEST

Clinically validated across premier research hospitals and gynecologists.

Did you know? Standard pregnancy tests detect hCG only 10–14 days after conception. SemSure detects seminal biomarkers instantly within 10–15 minutes up to 72 hours post-intercourse.

Research-Backed Problem Statement • Indian Reproductive Healthcare Market

Establishing the Problem: Misuse of Morning-After Pills & Unsafe Abortion in India

A comprehensive, data-driven synthesis examining contraceptive access barriers, the behavioural drivers of emergency pill overreliance, and the imperative for timely point-of-care verification.

01

Executive Problem Statement

India faces a significant reproductive healthcare challenge: unintended pregnancies remain widespread, while social stigma, limited access to routine contraception, and uncertainty about pregnancy risk can push women toward repeated reliance on emergency contraceptive pills and, in some circumstances, unsafe abortion practices.

The underlying problem is not simply a lack of awareness. Evidence from young Indian women's reproductive health conversations suggests that many women understand contraception but struggle to access methods that are private, convenient, affordable, and socially acceptable.

As a result, emergency contraception can become a substitute for planned, ongoing pregnancy prevention. When pregnancy remains uncertain, women may experience substantial anxiety, delay seeking appropriate medical advice, or face barriers to timely abortion care.

1

Contraceptive Access Gap

Women seeking reliable, routine contraception regularly encounter privacy concerns, provider bias, partner resistance, and systemic social stigma.

2

Overreliance on Morning-After Pills

Emergency contraceptive pills are repeatedly used as a practical fallback rather than an occasional, planned contingency protocol.

3

Unsafe Abortion Risk

Unintended pregnancies combined with clinical and cultural barriers increase exposure to unregulated abortion methods and delayed treatment.

Important Clinical Distinction: Repeated use of emergency contraception is not equivalent to abortion. Morning-after pills prevent ovulation or fertilization; they do not terminate an established pregnancy. The true problem is the unmet need for effective routine contraception, accurate risk assessment, and accessible reproductive healthcare.
02

The Scale of the Problem: What the Research Shows

~50%

Unintended Pregnancies

Of all pregnancies in India (2015, The Lancet study)

15.6M

Induced Abortions

Estimated nationally by The Lancet Global Health (2015)

67%

Classified as Unsafe

Abortions in India (2007–2011, cited in 2022 UNFPA report)

~8/day

Unsafe Abortion Deaths

National mortality burden reported by UNFPA (2022)

Understanding the Abortion Care Gap (The Lancet 2015 Breakdown)

The Lancet study estimated that of the 15.6 million induced abortions in India in 2015:

73%Medication abortions outside health facilities
22%Abortions conducted in certified health facilities
5%Other methods outside facilities (probably unsafe)

This distinction matters: The large proportion of abortions occurring outside health facilities demonstrates a vital need for accurate diagnostics, clinical guidance, quality-assured medication, and follow-up care rather than assuming all 73% were inherently unsafe.

03

Evidence of Reliance on Morning-After Pills

Insights from the 2026 "We Did Everything Right! Young Women and Their Birth Control Realities" report (5,200+ conversations analyzed)

72%~3,744 conversations

Pregnancy Anxiety

Fear of unintended pregnancy was present in 72% of conversations, even when emergency pills or other protection had already been used.

1,100+Active queries

Demand for Routine Methods

Women actively sought information regarding oral contraceptives, IUDs, and long-term protection, but described severe access barriers.

60%+From Tier-2 & Non-Metro

Need Beyond Major Metros

Inquiries originated across more than 500 locations, establishing that contraceptive anxiety is a nationwide phenomenon.

Why This Matters Clinically

Emergency contraceptive pills are safe for repeated use when needed and do not cause permanent infertility. However, they are significantly less effective as an ongoing strategy than planned methods and cause temporary menstrual irregularity that inflates pregnancy panic.

The real issue is therefore not that emergency pills cause severe physical injury, but rather the systemic overreliance on them due to the total absence of accessible, confidential routine verification tools.

04

Primary Market Research: Evidence from Indian Clinicians

Conducted with 60 clinicians across 10 Indian cities (Delhi, Mumbai, Kolkata, Bengaluru, Chennai, Hyderabad, etc.)

Research Metric2024 Estimates2029 ProjectionsStrategic Implication
Estimated Unintended Pregnancies17.0 Million16.4 MillionPersistently elevated volume requiring point-of-care screening.
Estimated Induced Abortions10.2 Million9.8 MillionSignifies widespread post-conception crisis management.

Source: Impeerical Consulting Market Potential Mapping (Feb 2025). Clinician-informed market projections highlighting barriers including partner resistance, social stigma, and restricted access for unmarried women.

05

Connecting the Evidence: How the Problem Develops

Conceptual pathway synthesized from clinical literature and market findings

Step 01

Limited Routine Access

Stigma, privacy concerns, partner resistance, and clinical gatekeeping.

Step 02

Morning-After Pill Fallback

Discreet and accessible at chemists, but not an ideal ongoing strategy.

Step 03

Pregnancy Risk Uncertainty

Crippling anxiety, menstrual shifts, and doubts over whether exposure occurred.

Step 04

Unintended Pregnancy Risk

No pill is 100% effective when taken too late or without verified exposure.

Step 05

Delayed or Unsafe Care

When confidential, timely clinical abortion options are inaccessible.

The Strategic Opportunity

The Fundamental Unmet Need: Accessible, Confidential, Evidence-Based Reproductive Diagnostics

"The fundamental unmet need is for accessible, confidential, evidence-based reproductive healthcare that helps women prevent unintended pregnancies, understand pregnancy risk, and obtain timely, safe medical care."

This represents an urgent market opportunity to strengthen preventive reproductive healthcare while eliminating uncertainty, improving informed decision-making, and mitigating the structural drivers of unintended pregnancy and unsafe abortion across India.

Sources and Evidence Strength

SourceScope & Best Use
Indian Express / UNFPA (2022) ↗Historical unsafe abortion burden and maternal health consequences in India.
The Lancet Global Health (Singh et al., 2018) ↗National epidemiological estimates of unintended pregnancies and 15.6M induced abortions in 2015.
Pinky Promise (2026 Report)Behavioral evidence across 5,200+ young women: pregnancy anxiety (72%), recurring EC queries, and access barriers.
Impeerical Consulting (Feb 2025)Clinical and commercial perspective from 60 clinicians across 10 major Indian metropolitan areas.
Important research note: The evidence documents clear gaps in routine contraception and reproductive healthcare access that contribute to emergency contraception overreliance and unintended pregnancy, while separate systemic barriers to safe abortion care increase potential harm.
Novel Technology Background
SEMSURE

Novel Technology

Our Dual-Biomarker Multiplex Assay enables reliable semen detection, even in challenging cases like Oligospermia. It features a Novel Universal Buffer for rapid biomarker extraction within just 1–2 minutes, all integrated into a Proprietary Cassette Design that ensures ease of use and high accuracy.

SemSure Rapid Semen Detection Kit on Podium

Biomarkers

The test detects two key biomarkers: Semenogellin and Prostate Acid Phosphatase.

Biological Samples

The test uses a vaginal swab as the biological sample, with semen detection possible for up to 3 days after exposure.

Universal Buffer Innovation

The Universal Buffer efficiently extracts biomarkers from the sample while also providing the required fluidity for accurate testing.

ASSURED Criteria
A

Affordable

Priced at just ₹90, making it highly accessible.

S

Sensitive

Delivers 99% accuracy in detecting semen.

S

Specific

Offers 100% reliability with minimal false results.

U

User-Friendly

A simple one-step assay for easy at-home use.

R

Rapid & Robust

Provides results within 10–15 minutes.

E

Equipment-Free

Requires no lab setup or instruments.

D

Deliverable

Designed for end-user convenience and portability.

Botanical Leaf Branch
Botanical Leaf Branch
Simple 4-Step Protocol

How to UseSemSure

Follow our quick video tutorial and 4 simple steps to get clinical-grade certainty at home in 10–15 minutes.

SemSure Video Tutorial
0:00 / 0:40
Swab Sample

Swab Sample

Gently collect the sample using the sterile collection swab.

Tap for full text ↓
Day 0 – 3 Viability
Swirl in Buffer

Swirl in Buffer

Swirl the swab in the universal buffer vial for 1–2 minutes to extract seminal biomarkers.

Tap for full text ↓
1–2 Min Mix
Add 2–3 Drops

Add 2–3 Drops

Dispense 2 to 3 drops of the extracted buffer solution into the cassette sample well (S).

Tap for full text ↓
Cassette Well
Read in 10–15 Min

Read in 10–15 Min

Read visual line results within 10 to 15 minutes to confirm presence with clinical certainty.

Tap for full text ↓
10–15 Min Window

Clear, Unambiguous Interpretation

Read results between 10 and 15 minutes. Do not interpret after 20 minutes.

Semen Detected
10–15 min

Positive Result

2 Red Lines (Control & Test)

SemSure Positive Result Cassette - 2 Red Lines

Both the Control (C) and Test (T) lines appear clearly. Indicates seminal biomarkers were detected. Immediate guidance and medical consultation are recommended.

No Semen Detected
10–15 min

Negative Result

1 Red Line (Control Line Only)

SemSure Negative Result Cassette - 1 Red Control Line

Only the Control (C) line appears; the Test (T) line is absent. Seminal biomarkers are absent. Eliminates the need for emergency hormonal pills.

Retest Recommended
10–15 min

Invalid Result

No Control Line Detected

SemSure Invalid Result Cassette - No Control Line
!

If the Control line fails to appear, the test is invalid even if a Test line is visible. Repeat the test with a fresh device and buffer.

Patented & Officially Registered Design

SemSure™ represents proprietary innovation granted by the Patent Office, Government of India.

Patent Certificate

Patent No. 573973

Govt. of India
Government of India Patent Certificate No. 573973 for SemSure Diagnostic Kit

The Patent Office, Government of India

Title: A novel point-of-care diagnostic kit for detection of semen samples in general sexual wellness and forensic examinations

Design Registration

Design No. 387848-001

Class 24-01
Government of India Certificate of Registration of Design No. 387848-001

Certificate of Registration of Design

Application of proprietary industrial design to SEMEN DETECTION KIT

FAQ's

SemSure™ & Wellness FAQs: Find Your Answers

Explore frequently asked questions about SemSure™ rapid detection, testing window, clinical accuracy, and emergency contraception guidance.

10 Topics • Scroll to view all questions
LET'S CONNECT

Have Questions? We're Here to Help.

Reach out to us for product inquiries, partnerships or more information.